Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (11926)	12/1/1997 9:18:00 AM
From: Henry Niman	Respond to of 32384

Stan, When the relabling first came out there was concern. However, virtually all users reported positive experiences so it does look like the risk reward ratio is low. However, this morning one user did report hair loss, which I hadn't heard before.

To: squetch who wrote (11926)	12/1/1997 9:22:00 AM
From: Henry Niman	Respond to of 32384

Here's one of the messages that I received this morning: Subject: Re: Rezulin Date: Sun, 30 Nov 97 17:29:00 +0000 From: Leah Owens <leaho@dmv.com> Reply-To: diabetic@Lehigh.EDU To: Diabetes Discussion List <diabetic@Lehigh.EDU> References: 1 Becareful I had the bad side effect of causing your hair to fall out. It did me. I stopped taking it 2 weeks ago to see and no more hair falling out.

To: squetch who wrote (11926)	12/1/1997 9:32:00 AM
From: Henry Niman	Respond to of 32384

Here's one of my earlier posts on TZDs: techstocks.com Here's one of my posts on the newer TZDs (and it was Takeda's pioglitazone) that is used at 1/10 the concentration - I'm not sure about SBH's drug - However, LGND's rexinoids synergize with both): techstocks.com

To: squetch who wrote (11926)	12/1/1997 9:35:00 AM
From: Henry Niman	Respond to of 32384

Stan, I think that WLA's bid is down to 122 (about 18 points below Friday's close).

To: squetch who wrote (11926)	12/1/1997 9:38:00 AM
From: Henry Niman	Respond to of 32384

Here's what the London Finacial Times had to say today: Glaxo suspends diabetes drug in UK Glaxo Wellcome has suspended the UK availability of its Troglitazone drug, used for the treatment of Type 2 diabetes, amid concerns about its safety. About 5,000 patients in the UK have been prescribed the drug since it became available on October 1 this year.

To: squetch who wrote (11926)	12/1/1997 9:44:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Here's one of the abstracts reporting Rexinoid synergizatiion with Takeda's second generation TZD (CNBC just announced that WLA was slated to open between 118 and 122): Proc Natl Acad Sci U S A 1997 Jan 7;94(1):237-241 Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM Induction of terminal differentiation represents a promising therapeutic approach to certain human malignancies. The peroxisome proliferator-activated receptor gamma (PPAR gamma) and the retinoid X receptor alpha (RXR alpha) form a heterodimeric complex that functions as a central regulator of adipocyte differentiation. Natural and synthetic ligands for both receptors have been identified. We demonstrate here that PPAR gamma is expressed at high levels in each of the major histologic types of human liposarcoma. Moreover, primary human liposarcoma cells can be induced to undergo terminal differentiation by treatment with the PPAR gamma ligand pioglitazone, suggesting that the differentiation block in these cells can be overcome by maximal activation of the PPAR pathway. We further demonstrate that RXR-specific ligands are also potent adipogenic agents in cells expressing the PPAR gamma/RXR alpha heterodimer, and that simultaneous treatment of liposarcoma cells with both PPAR gamma- and RXR-specific ligands results in an additive stimulation of differentiation. Liposarcoma cell differentiation is characterized by accumulation of intracellular lipid, induction of adipocyte-specific genes, and withdrawal from the cell cycle. These results suggest that PPAR gamma ligands such as thiazolidinediones and RXR-specific retinoids may be useful therapeutic agents for the treatment of liposarcoma. PMID: 8990192, UI: 97144425